Kombinationstherapie von schweren Onychomykosen – Empfehlungen eines Expertengremiums

Zusammenfassung

Onychomykosen sind schwer behandelbare Pilzinfektionen des Nagelorgans mit einer hohen Rezidivrate. Klinische Studien zeigen, dass bei gesicherter schwerer Nagelmykose durch Dermatophyten eine Steigerung der kompletten Heilungsrate (mykologisch plus klinisch) durch eine Kombinationsbehandlung mit lokal applizierten und oral verabreichten Antimykotika im Vergleich zur systemischen Monotherapie erreicht werden kann. Am besten untersucht sind Regime mit kontinuierlich täglicher Einnahme von Terbinafin und wöchentlicher Applikation eines Amorolfin-haltigen Nagellacks. Eine topische Monotherapie mit einem Nagellack kommt v. a. bei einer superfiziellen weißen Onychomykose (SWO) oder einer distal-subungualen Onychomykose (DSO) mit einem geringeren Befallsgrad ohne Beteiligung der Matrix infrage. Die mechanische Entfernung des infizierten Nagelmaterials und hygienische Maßnahmen unterstützen die Therapie. Kritisch für die Erfolgsaussichten ist eine hohe Langzeitadhärenz der Patienten. Die Therapie sollte bis zum Auftreten der Erscheinungsfreiheit andauern. Anschließend empfiehlt sich eine dauerhafte Rezidivprophylaxe mit antimykotischem Nagellack.

Abstract

Onychomycoses are difficult-to-treat infections of the nail plate with a high recurrence rate. Clinical studies show an increase of the complete cure rate (mycological plus clinical) of severe onychomycoses for documented dermatophytic onychomycoses with combination therapies of locally applied and orally administered antifungals. The best studied regimens involve continuous daily use of terbinafine and weekly application of amorolfine nail lacquer. A topical monotherapy with a nail varnish may be considered especially for superficial white onychomycosis or distal subungual onychomycosis with a lower percentage of affected nail area without involvement of the nail matrix. Repeated mechanical removal of infected nail material and hygienic measures support the efficacy of the treatment. High long-term adherence is critical for optimal success rates. The treatment should be continued until resolution of signs and symptoms. Subsequent long-term secondary prophylaxis with an antifungal nail lacquer is recommended.

Publikationsverlauf

Artikel online veröffentlicht:
30. April 2020

• Literatur

• 1 Ghannoum M, Long L, Kunze G. et al. A pilot, layerwise, ex vivo evaluation of the antifungal efficacy of amorolfine 5 % nail lacquer vs other topical antifungal nail formulations in healthy toenails. Mycoses 2019; 62: 494-501
• 2 Iorizzo M, Hartmane I, Derveniece A. et al. Ciclopirox 8 % HPCH NailLacquer in the Treatment of Mild-to-Moderate Onychomycosis: A Randomized, Double-Blind Amorolfine Controlled Study Using a Blinded Evaluator. Skin Appendage Disord 2016; 1: 134-140 [Eine hierzu vorliegende Publikation ist wegen methodischer Probleme nicht interpretierbar.]
• 3 Reinel D. Wo liegen die Grenzen der Wissenschaft? – Hundertprozentige Eradikation der Erreger bei Onychomykosen? Wunsch und Wirklichkeit. Akt Dermatol 2019; 45: 365-366
• 4 Schaller M, Sigurgeirsson B, Sarkany M. Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5 % nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis. Mycoses 2017; 60: 800-807
• 5 Schaller M, Braunsdorf C, Mailänder-Sanchez D. et al. Comparison of user-friendliness and treatment cost of Loceryl^® vs. Ciclopoli^® – a patientʼs perspective. Mycoses 2015; 58: 632-636
• 6 Sigurgeirsson B, Ghannoum MA, Osman-Ponchet H. et al. Application of cosmetic nail varnish does not affect the antifungal efficacy of amorolfine 5 % nail lacquer in the treatment of distal subungual toenail onychomycosis: results of a randomised active-controlled study and in vitro assays. Mycoses 2016; 59: 319-326
• 7 Gupta AK, Daigle D, Foley KA. Topical therapy for toenail onychomycosis: an evidence-based review. Am J Clin Dermatol 2014; 15: 489-502
• 8 Ameen M, Lear JT, Madan V. et al. British Association of Dermatologistsʼ guidelines for the management of onychomycosis 2014. Br J Dermatol 2014; 171: 937-958
• 9 Fachinformation Loceryl^® . Stand: September 2019
• 10 Bräutigam M, Nolting S, Schopf RE. et al. German randomized double-blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. Br J Dermatol 1996; 134 (Suppl. 46) 18-21 discussion 38
• 11 Bräutigam M, Nolting S, Schopf RE. et al. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ 1995; 311: 919-922 Erratum in: BMJ 1995; 311 (7016): 1350
• 12 Schatz F, Bräutigam M, Dobrowolski E. et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995; 20: 377-383
• 13 Seidl HP, Jäckel A, Müller J. et al. Sporicidal effect of amorolfine and other antimycotics used in the therapy of fungal nail infections. Mycoses 2015; 58: 610-619
• 14 Gupta AK, Foley KA, Mays RR. et al. Monotherapy for toenail onychomycosis: a systematic review and network meta-analysis [Epub ahead of print]. Br J Dermatol 2019; DOI: 10.1111/bjd.18155.
• 15 Sigurgeirsson B, Olafsson JH, Steinsson JT. et al. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol 2010; 24: 910-915
• 16 Shemer A, Gupta AK, Kamshov A. et al. Topical antifungal treatment prevents recurrence of toenail onychomycosis following cure. Dermatol Ther 2017; 30 DOI: 10.1111/dth.12545.
• 17 Baran R, Feuilhade M, Combernale P. et al. A randomized trial of amorolfine 5 % solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol 2000; 142: 1177-1183
• 18 Baran R, Sigurgeirsson B, de Berker D. et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol 2007; 157: 149-157
• 19 Jaiswal A, Sharma RP, Garg AP. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8 % or topical amorolfine hydrochloride 5 % in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol 2007; 73: 393-396
• 20 Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. Br J Dermatol 2001; 145 (Suppl. 60) 21-26
• 21 Rigopoulos D, Katoulis AC, Ioannides D. et al. A randomized trial of amorolfine 5 % solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis. Br J Dermatol 2003; 149: 151-156
• 22 Chandra S, Sancheti K, Podder I. et al. A Randomized, Double-blind Study of Amorolfine 5 % Nail Lacquer with Oral Fluconazole Compared with Oral Fluconazole Alone in the Treatment of Fingernail Onychomycosis. Indian J Dermatol 2019; 64: 253-260
• 23 Feng X, Xiong X, Ran Y. Efficacy and tolerability of amorolfine 5 % nail lacquer in combination with systemic antifungal agents for onychomycosis: A meta-analysis and systematic review. Dermatol Ther 2017; 30 DOI: 10.1111/dth.12457.
• 24 Gupta AK. Onychomycosis Combination Therapy Study Group. Ciclopirox topical solution, 8 % combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J Drugs Dermatol 2005; 4: 481-485
• 25 Avner S, Nir N, Henri T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatolog Treat 2005; 16: 327-330
• 26 Schaller M, Nabhani H. Synergistic effect of amorolfine and terbinafine in vitro. DMykG 2019; XX: Poster PIII-6
• 27 Nenoff P, Krüger C, Paasch U. et al. Mykologie – ein Update. Teil 3: Dermatomykosen: topische und systemische Behandlung. JDDG 2015; 13: 387-413
• 28 Kawa N, Lee KC, Anderson RR. et al. Onychomycosis: A Review of New and Emerging Topical and Device-based Treatments. J Clin Aesthet Dermatol 2019; 12: 29-34
• 29 Gupta AK, Stec N. Recent advances in therapies for onychomycosis and its management. F1000Res 2019; Jun 25; 8: pii: F1000 Faculty Rev-968 DOI: 10.12688/f1000research.18646.1. eCollection 2019.
• 30 Gupta AK, Versteeg SG. A critical review of improvement rates for laser therapy used to treat toenail onychomycosis. J Eur Acad Dermatol Venereol 2017; 31: 1111-1118